Estimated geographical and temporal distribution of lung-cancer incidence varied across the four main subtypes worldwide. Our ...
Medical Xpress on MSN14d
Study reveals novel insights into the molecular pathology of esophageal squamous cell carcinomaEsophageal squamous cell carcinoma (ESCC) is a highly aggressive malignancy ... This discovery provides new insights into the ...
In contrast, the sensitivity of IFSH for predicting final surgical margin status was low, at 21.7%. This indicates that while IFSH is effective for ruling out residual disease, it misses a substantial ...
Newser on MSN3d
Lung Cancer Rising in Never-SmokersCases of lung cancer in people who've never smoked cigarettes or tobacco are increasing, along with evidence suggesting air ...
NSCLC can be further subdivided into: lung adenocarcinoma (ADC), large cell carcinoma and squamous cell carcinoma (SCC). These cancer subtypes have distinct morphologies and molecular profiles ...
EMA committee recommends extension of marketing authorisation for Janssen-Cilag’s subcutaneous Rybrevant to treat advanced EGFR-mutated NSCLC: Beerse, Belgium Tuesday, February ...
Symptoms and treatment options depend on the stage of your lung cancer along with what type of NSCLC you're diagnosed with. There are three primary types: adenocarcinoma, squamous cell carcinoma, and ...
Volrustomig is under clinical development by AstraZeneca and currently in Phase III for Squamous Non-Small Cell Lung Cancer. According to GlobalData, Phase III drugs for Squamous Non-Small Cell Lung ...
SIB-001 is under development for the treatment of squamous non-small cell lung carcinoma, recurrent or metastatic head and neck squamous cell carcinoma, squamous non-small cell lung cancer, epithelium ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback